Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 7, 2024
Daily News
February 7, 2024
- Japan to Revamp Scheme for Drug Maker’s Reporting of Supply Concerns in April
February 7, 2024
- Legal Changes on Horizon for GMP Inspection Authorities, Other Regulation Panel Topics?
February 7, 2024
- 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
- Navigating the Evolving Landscape of Medical Affairs: Integrating Insights and Identity for Future Success
February 7, 2024
- Govt Eyes Boosted Manpower at AMED towards Next 5-Year Plan from FY2025
February 7, 2024
- CEO Bids Farewell to Mitsubishi Chemical after Group Revamp
February 7, 2024
- Keytruda Tops Japan Sales Ranking for 4th Month in January: Encise
February 7, 2024
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…